XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 9 Months Ended
Dec. 28, 2024
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
16. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Net revenues(1)
Plasma$134,389 $147,560 $408,996 $429,694 
Blood Center70,730 73,528 206,373 213,167 
Hospital144,248 116,625 417,038 325,003 
Net revenues in constant currency349,367 337,713 1,032,407 967,864 
Effect of exchange rates(825)(1,463)(2,182)(2,099)
Net revenues$348,542 $336,250 $1,030,225 $965,765 
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
Segment operating income
Plasma$70,337 $80,450 $205,902 $234,190 
Blood Center26,955 27,654 76,744 81,244 
Hospital62,114 49,355 175,710 132,132 
Segment operating income159,406 157,459 458,356 447,566 
Corporate expenses (1)
(70,273)(83,694)(214,660)(234,753)
Effect of exchange rates304 (401)267 (879)
Amortization of acquired intangible assets(12,230)(6,911)(36,965)(21,606)
Amortization of fair value inventory step-up(3,341)— (12,319)— 
Integration and transaction costs(244)(4,869)(13,449)(7,768)
Restructuring costs(3,515)(7,968)(12,929)(8,043)
Restructuring related costs(1,468)(2,403)(5,557)(6,554)
Digital transformation costs(4,620)(3,415)(15,823)(10,712)
Write downs of certain assets and PCS2 related charges(4,000)(210)(4,000)(621)
MDR and IVDR costs(1,008)(1,433)(3,125)(4,587)
Litigation-related charges18 (177)(1,057)(6,684)
Impairment of intangible assets— — (2,391)(10,419)
Gain on sale of property, plant and equipment— — 14,134 — 
Operating income$59,029 $45,978 $150,482 $134,940 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

Net revenues by business unit are as follows:
  Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
 Plasma$134,224 $147,641 $408,695 $430,056 
Apheresis55,388 52,565 158,814 156,704 
Whole Blood14,957 19,814 46,304 54,537 
 Blood Center70,345 72,379 205,118 211,241 
Interventional Technologies(1)
63,253 43,007 188,220 119,168 
Blood Management Technologies(2)
80,720 73,223 228,192 205,300 
 Hospital143,973 116,230 416,412 324,468 
Net revenues(3)
$348,542 $336,250 $1,030,225 $965,765 
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months EndedNine Months Ended
(In thousands)December 28,
2024		December 30,
2023		December 28,
2024		December 30,
2023
United States$257,665 $250,804 $762,628 $724,222 
Japan16,174 14,825 46,303 41,609 
Europe44,163 37,035 133,379 115,088 
Rest of Asia25,597 30,935 71,148 80,710 
Other4,943 2,651 16,767 4,136 
Net revenues$348,542 $336,250 $1,030,225 $965,765